Banner Life Sciences Drug Patent Portfolio
Banner Life Sciences owns 1 orange book drug protected by 21 US patents Given below is the list of Banner Life Sciences's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11590095 | Fumarate ester dosage forms | 18 Mar, 2036 | Active |
| US10945985 | Fumarate ester dosage forms | 14 Aug, 2035 | Active |
| US10918615 | Fumarate esters | 12 Aug, 2035 | Active |
| US10918617 | Fumarate ester pharmaceutical compositions | 10 Aug, 2035 | Active |
| US10918616 | Fumarate ester pharmaceutical compositions | 03 Jun, 2035 | Active |
| US10098863 | Fumarate esters | 27 Feb, 2035 | Active |
| US10105335 | Fumarate ester dosage forms | 27 Feb, 2035 | Active |
| US10105336 | Fumarate ester pharmaceutical compositions | 27 Feb, 2035 | Active |
| US10105337 | Fumarate ester pharmaceutical compositions | 27 Feb, 2035 | Active |
| US11903918 | Fumarate ester dosage forms with enhanced gastrointestinal tolerability | 27 Feb, 2035 | Active |
| US9326947 | Controlled release fumarate esters | 27 Feb, 2035 | Active |
| US9326965 | Controlled release fumarate esters | 27 Feb, 2035 | Active |
| US9511043 | Fumarate ester pharmaceutical compositions | 27 Feb, 2035 | Active |
| US9517209 | Fumarate ester pharmaceutical compositions | 27 Feb, 2035 | Active |
| US9566259 | Fumarate ester dosage forms | 27 Feb, 2035 | Active |
| US9636318 | Fumarate ester dosage forms | 27 Feb, 2035 | Active |
| US9636319 | Fumarate ester dosage forms | 27 Feb, 2035 | Active |
| US9814691 | Fumarate ester pharmaceutical compositions | 27 Feb, 2035 | Active |
| US9814692 | Fumarate ester dosage forms | 27 Feb, 2035 | Active |
| US9820960 | Fumarate ester pharmaceutical compositions | 27 Feb, 2035 | Active |
| US9820961 | Fumarate ester dosage forms | 27 Feb, 2035 | Active |
Latest Legal Activities on Banner Life Sciences's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Banner Life Sciences.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Jun, 2024 | US9517209 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Jun, 2024 | US9511043 |
| Mail Patent eGrant Notification | 20 Feb, 2024 | US11903918 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 20 Feb, 2024 | US11903918 |
|
Recordation of Patent Grant Mailed
Critical
| 20 Feb, 2024 | US11903918 |
| Recordation of Patent eGrant | 20 Feb, 2024 | US11903918 |
|
Email Notification
Critical
| 20 Feb, 2024 | US11903918 |
| Patent eGrant Notification | 20 Feb, 2024 | US11903918 |
|
Email Notification
Critical
| 01 Feb, 2024 | US11903918 |
|
Issue Notification Mailed
Critical
| 31 Jan, 2024 | US11903918 |
| Dispatch to FDC | 17 Jan, 2024 | US11903918 |
|
Issue Fee Payment Received
Critical
| 04 Jan, 2024 | US11903918 |
| Response to Reasons for Allowance | 04 Jan, 2024 | US11903918 |
|
Issue Fee Payment Verified
Critical
| 04 Jan, 2024 | US11903918 |
|
Mail Notice of Allowance
Critical
| 28 Dec, 2023 | US11903918 |
Banner Life Sciences's Family Patents
Banner Life Sciences drugs have patent protection in a total of 7 countries. It has a significant patent presence in the US with 69.4% of its patents being US patents. Click
below to unlock the full patent family tree.
Banner Life Sciences Drug List
Given below is the complete list of Banner Life Sciences's drugs and the patents protecting them.
1. Bafiertam
Bafiertam is protected by 21 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11590095 | Fumarate ester dosage forms |
18 Mar, 2036
(11 years from now)
| Active |
| US10945985 | Fumarate ester dosage forms |
14 Aug, 2035
(10 years from now)
| Active |
| US10918615 | Fumarate esters |
12 Aug, 2035
(10 years from now)
| Active |
| US10918617 | Fumarate ester pharmaceutical compositions |
10 Aug, 2035
(10 years from now)
| Active |
| US10918616 | Fumarate ester pharmaceutical compositions |
03 Jun, 2035
(10 years from now)
| Active |
| US10098863 | Fumarate esters |
27 Feb, 2035
(10 years from now)
| Active |
| US10105335 | Fumarate ester dosage forms |
27 Feb, 2035
(10 years from now)
| Active |
| US10105336 | Fumarate ester pharmaceutical compositions |
27 Feb, 2035
(10 years from now)
| Active |
| US10105337 | Fumarate ester pharmaceutical compositions |
27 Feb, 2035
(10 years from now)
| Active |
| US11903918 | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
27 Feb, 2035
(10 years from now)
| Active |
| US9326947 | Controlled release fumarate esters |
27 Feb, 2035
(10 years from now)
| Active |
| US9326965 | Controlled release fumarate esters |
27 Feb, 2035
(10 years from now)
| Active |
| US9511043 | Fumarate ester pharmaceutical compositions |
27 Feb, 2035
(10 years from now)
| Active |
| US9517209 | Fumarate ester pharmaceutical compositions |
27 Feb, 2035
(10 years from now)
| Active |
| US9566259 | Fumarate ester dosage forms |
27 Feb, 2035
(10 years from now)
| Active |
| US9636318 | Fumarate ester dosage forms |
27 Feb, 2035
(10 years from now)
| Active |
| US9636319 | Fumarate ester dosage forms |
27 Feb, 2035
(10 years from now)
| Active |
| US9814691 | Fumarate ester pharmaceutical compositions |
27 Feb, 2035
(10 years from now)
| Active |
| US9814692 | Fumarate ester dosage forms |
27 Feb, 2035
(10 years from now)
| Active |
| US9820960 | Fumarate ester pharmaceutical compositions |
27 Feb, 2035
(10 years from now)
| Active |
| US9820961 | Fumarate ester dosage forms |
27 Feb, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bafiertam's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List